These findings led to the FDA approval of nivolumab (3 mg/kg) plus ipilimumab (1 mg/kg) for first-line treatment of advanced NSCLC with PD-L1 ≥1% in 2020 (Table 2). The gene discussed is CD274; the disease is non-small cell lung carcinoma.